** Drugmaker's shares up 0.33 pct at $47.52 in heavypremarket trade
** Analysts from Goldman Sachs upgraded their rating on thecompany's stock to "buy" from "neutral", citing safe dividends, sustainable franchises and optionality on more structural changeas key reasons
** "On a slightly longer-dated time horizon, we believethere is optionality on more meaningful structural change (suchas selling off its vaccines/consumer health businesses to unlockmore significant shareholder value)," analysts wrote in the note